These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24051302)

  • 21. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance study on the tolerability and safety of Flebogamma
    Alsina L; Mohr A; Montañés M; Oliver X; Martín E; Pons J; Drewe E; Papke J; Günther G; Chee R; Gompels M;
    Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An application of mass spectrometry for quality control of biologicals: Highly sensitive profiling of plasma residuals in human plasma-derived immunoglobulin.
    Limonier F; Van Steendam K; Waeterloos G; Brusselmans K; Sneyers M; Deforce D
    J Proteomics; 2017 Jan; 152():312-320. PubMed ID: 27894965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of an intravenous immunoglobulin with improved safety and functional activity.
    Roberts PL; Dolan T; Paddick M; Stagg S; More JE
    Biologicals; 2015 Mar; 43(2):123-9. PubMed ID: 25498751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays.
    Liang Y; Jackson JW; Woodle SA; Surov SS; Parunov LA; Scott DE; Weinstein M; Lee TK; Ovanesov MV
    Res Pract Thromb Haemost; 2021 Jan; 5(1):211-222. PubMed ID: 33537546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma.
    Berger M;
    J Clin Immunol; 2007 Nov; 27(6):628-33. PubMed ID: 17909953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.
    Radosevich M; Burnouf T
    Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products.
    Wilmot HV; Gray E
    Vox Sang; 2021 Jul; 116(6):656-664. PubMed ID: 33277936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and Sindbis viruses) from an intravenous immunoglobulin preparation.
    Hamamoto Y; Harada S; Yamamoto N; Uemura Y; Goto T; Suyama T
    Vox Sang; 1987; 53(2):65-9. PubMed ID: 2825431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of the contact system in patients with a first acute myocardial infarction.
    Konings J; Govers-Riemslag JW; Spronk HM; Waltenberger JL; ten Cate H
    Thromb Res; 2013 Jul; 132(1):138-42. PubMed ID: 23746628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity.
    Mina A; Favaloro EJ; Koutts J
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):203-7. PubMed ID: 22322136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined thrombogenic effects of vessel injury, pregnancy and procoagulant immune globulin administration in mice.
    Xu Y; Liang Y; Parunov L; Despres D; Eckhaus M; Scott D; Ovanesov M; Struble EB
    Thromb J; 2020 Nov; 18(1):32. PubMed ID: 33292285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.
    Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C
    Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Technology of immunoglobulin production. I. Technological aspects of purification].
    Volkov GL
    Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.
    Klaver AC; Coffey MP; Smith LM; Loeffler DA
    Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.
    Berger M; Pinciaro PJ; Althaus A; Ballow M; Chouksey A; Moy J; Ochs H; Stein M
    J Clin Immunol; 2010 Mar; 30(2):321-9. PubMed ID: 19997861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.